Phytopharm Plc, which is developing products derived from medicinal plants for treating neurodegenerative diseases, has appointed Roger Hickling as its new research and development director and board director.
Mr Hickling is a former R&D director of Alizyme Therapeutics Plc. Altogether he has 30 years of experience in developing medical products including regulatory expertise.
Phytopharm has two neurotrophic factor products in clinical development. One is being investigated for Parkinson's disease, Alzheimer’s disease and Huntington’s disease and the other for amyotrophic lateral sclerosis (ALS), among other indications.
Copyright 2010 Evernow Publishing Ltd